By SmashMeals Editorial · Published · Updated
For about 30 years, the treatment for celiac disease has been a single instruction: avoid gluten for life. In 2026 that is still the rule, but the list of medicines in testing is longer and more serious than ever. Here is a plain-language guide to where things stand, what each approach is trying to do, and what it means for your plate today.
This guide summarizes research and is not medical advice. No medicine is approved by the FDA to treat celiac disease.
Why a medicine is so hard to build
Celiac disease is an autoimmune condition. When someone with celiac disease eats gluten, immune cells treat certain gluten fragments as a threat and attack the lining of the small intestine. Even small, repeated exposures can keep that process going. A 2026 study found immune activation at doses of just a few milligrams of gluten; see our guide to how much gluten is too much.
Researchers are attacking the problem at different points: breaking down gluten before it can cause harm, calming the immune signals that drive damage, and teaching the immune system to tolerate gluten.
The 2026 pipeline at a glance
| Candidate | Company | Approach | Stage (as of Oct. 2026) |
|---|---|---|---|
| FB102 | argenx (from Forte Biosciences) | Antibody blocking CD122, a receptor for inflammatory IL-2 and IL-15 signals | Phase 2 met primary endpoint (Oct. 8, 2026); Phase 3 planned |
| ANB033 | First Tracks Biotherapeutics | CD122 antagonist | Phase 1b; topline data expected Q4 2026 |
| Amlitelimab | Sanofi | Antibody, studied in people who still have damage on a gluten-free diet | Phase 2a/b; enrollment complete, data expected 2027 |
| DONQ52 | Chugai | Investigational, studied in people with ongoing damage and symptoms | Phase 2, recruiting |
| VTP-1000 | Barinthus Biotherapeutics | Nanoparticles with gluten peptides, aiming to build tolerance | Phase 1 |
Sources: argenx and The Flare's 2026 pipeline review. Trial stages change; check ClinicalTrials.gov for current status.
The FB102 result in more detail
On October 8, 2026, argenx reported that FB102 met the primary endpoint of a 126-patient Phase 2 trial. Adults who had been symptom-free on a gluten-free diet for at least a year were randomized to two doses of FB102 or placebo during an eight-week gluten challenge. The main measure, the villus height-to-crypt depth ratio from intestinal biopsies, favored FB102 (p=0.0176). Effect sizes were not released, and the data have not yet been peer-reviewed. Read our news coverage.
What these medicines are likely to do, and not do
Most candidates are being tested as a backup to the diet, not a replacement. In plain terms, the near-term goal is protection from accidental exposure, the crumb in a shared toaster or the sauce that turned out not to be gluten-free, and healing for people whose intestines stay damaged despite a strict diet.
Even if a drug succeeds in Phase 3, approval, pricing, insurance coverage and long-term safety data are years of work. Your doctor will decide whether a future medicine fits your situation.
| Question | Realistic answer today |
|---|---|
| Can I stop eating gluten-free? | No. Until a medicine is approved and your doctor advises otherwise, strict avoidance remains the treatment. |
| When could the first drug be approved? | Unknown. Phase 3 trials typically take years. |
| Can I join a trial? | Possibly. Ask your gastroenterologist and search ClinicalTrials.gov or the Celiac Disease Foundation's resources. |
| Will it be covered by insurance? | Unknown until approval and pricing. |
Staying informed without the hype
Company press releases are the first word, not the last. Look for peer-reviewed publications and presentations at medical meetings. The Celiac Disease Foundation launched Inside Celiac, a monthly podcast covering research and trials, on October 15, 2026, a good way to follow developments.
Meanwhile, make the diet easier
The best thing you can do this week is reduce the effort and risk of eating gluten-free. That means fewer guess-the-ingredients restaurant meals and a reliable plan for busy days.
SmashMeals operates a dedicated gluten-free kitchen, so we do not run a regular wheat-based production line beside a gluten-free line. Cross-contact can still occur elsewhere in the food system, and gluten is not the only allergen, so review each meal's ingredients and ask us questions before ordering. Read our gluten-free standards, see the newly diagnosed celiac guide, and browse this week's menu.
Sources
Frequently asked questions
- Is there a cure for celiac disease in 2026?
- No. No medicine is FDA-approved to treat celiac disease. Several candidates are in clinical trials, and a strict gluten-free diet remains the treatment.
- What is FB102?
- An investigational antibody that blocks CD122, a receptor for inflammatory IL-2 and IL-15 signals. In October 2026 argenx reported it met its Phase 2 primary endpoint in celiac disease.
- Will celiac drugs let me eat gluten?
- That is not the near-term goal. Most candidates are being studied to protect against accidental exposure or heal ongoing damage, alongside a gluten-free diet.